Several observers have reported that plasmas differ in their susceptibility to staphylocoagulase. Chapman' tested 81 fresh human blood samples with a ten-hour staphylococcus culture, and noted that at two hours firm clots had formed with 35, partial clots with 25, while 21 bloods remained unclotted. The suggestion that such variation in human plasmas may be due to the activity of "inhibitors" has received support from the observation that slightly diluted plasmas may be clotted more rapidly than are the undiluted samples. Fisher' and Cruikshank4 therefore advocated the use of plasma diluted 1:10 for routine coagulase testing. Chapman2 and his associates, working with rabbit plasma, recommend a dilution of 1:4, but found higher dilutions unsatisfactory. However, no attempt was made to restore fibrinogen to the diluted plasma. Lominski and Roberts' approached the problem by titrating serum for the limiting dilution which would inhibit the clotting of plasma by coagulase. Of 348 sera, 212 contained inhibitory substances. On the other hand, 104 plasmas subjected to the same test only rarely inhibited coagulation, and then only in the undiluted state. The authors explain this difference in the behavior of serum and plasma on a greater affinity of coagulase for fibrinogen than for the inhibitory substance. Smith and Hale,8 in a test of 40 human plasmas noted one which failed to clot with viable staphylococci, and gave a low titer with a cell-free filtrate. They suggest-' that this is due not so much to inhibitory substances, as to a lack of the "activator" in the plasma.
gained support from a combined collodion particle and neutralization test, in which the neutralizing bodies were specifically adsorbed by the coagulase-coated collodion particles. Rammelkamp7 reported that monkeys develop a rising titer of anticoagulase following immunization with cell-free coagulase, and that human acute and convalescent phase sera of patients with staphylococcal infection showed an increase in the anticoagulase titer in later blood samples.
Earlier observations on coagulase inhibition have been carried out with living cultures, or at best with relatively weak cell-free filtrates. By the use of a standardized quantitative technique utilizing a relatively potent cell-free coagulase preparation, the present study attempts to define the base line for the susceptibility of human plasma to this agent, and to indicate whether the observed variations may be ascribed entirely to one or another of the proposed mechanisms of interference.
Materials and methods Human plasma. Plasma was obtained from the blood bank, from prospective blood donors, and from clinic patients.* The blood bank plasma was prepared with an anti-coagulant of citrate-citric acid glucose solution, 10 per cent by volume. The other blood samples were drawn into a 0.25 per cent solution of sodium citrate, also 10 per cent by volume. The clinic and donor bloods were titrated immediately, while the blood bank material varied in age from 24 hours to 4 weeks. Clotted samples were avoided. Such blood as was released before the expiration date was regarded as unsuitable for clinical use, because of positive serology, or, rarely, was returned from the wards because of transfusion reaction. Preliminary studies established that the inhibitory activity of the blood bank plasma was not due to age or to citrate excess. All red cells were removed by centrifugation.
Coagulase. In all tests, the same stable cell-free coagulase solution was used. It was preserved with 1:10,000 merthiolate and was kept in the refrigerator at all times. When this stock solution was tested against a "non-inhibitory" plasma, coagulation occurred at 370 C. in 24 hours with a coagulase dilution of 1:5120 to 1:10,240. The titration technique, previously detailed,10 consisted essentially in making serial two-fold dilutions of coagulase in two per cent peptone-saline in a volume of 0.5 ml., adding 0.5 ml. of undiluted plasma, and maintaining a final merthiolate concentration of 1:10,000. The progress of the reaction was observed at various time intervals up to 24 hours in a water-bath at 370 C.
The coagulase-feacting factor. The titration technique has been described elsewhere."
Serum neutralization test. The Lominski and Roberts6 methods were followed. Since Lominski and Roberts found that 212 of 348 human sera inhibit the coagulase-plasma reaction, an attempt was made to determine whether any parallelism exists between their procedure and the one adopted in the present study. Thirteen plasmas were accordingly recalcified, and titrations were carried out by both methods (Table 2 ).
It will be noted that a general parallelism exists in the results obtained by the two techniques. It should be pointed out, however, that unless the optimal dilution of coagulase is used, erroneous results may be obtained, since an excess of coagulase may mask serum neutralization. Also, other than quantitative considerations may be involved, since an immune rabbit serum, seemingly of comparable activity to an inhibitory human plasma when tested as plasma by the coagulase dilution method, proved far more effective than the human sample when used in a serum neutralization test. In view of the suggestion that the resistance of human plasma to coagulase might represent a deficiency8'9 of "activator" or coagulasereacting factor, a series of 100 plasmas, varying widely in their resistance to coagulase, were also tested for reacting-factor content. The technique, previously detailed,11 consisted essentially in simultaneously titrating serial coagulase dilutions against ten-fold plasma dilutions, with the appropriate addition of bovine fibrinogen beyond the undiluted plasma level. The coagulase-fibrinogen and plasma-fibrinogen controls remained negative. The same stable coagulase preparation was used for all tests. In Table 3 Table 3 whether inhibitory human blood behaves similarly. Since Cavelti has reported that older human blood may cause non-specific agglutination, the study was limited to freshly drawn material. Fifty sera were tested without knowledge of their plasma resistance titers. None of these showed any collodion particle agglutination. Forty additional fresh specimens were obtained from the dermatology clinic; of these, 10 were highly inhibitory with titers of 0 to 1:80, and 9 moderately resistant, with titers of 1:100 to 1:640. Only one of these patients was acutely ill: a young man with reactivated lupus vulgaris, with superimposed secondary infection and fever. His plasma was inhibitory, coagulase-coated collodion particles were agglutinated by a serum dilution of 1:8. None of the other specimens caused any collodion particle agglutination.
Discussion
As has been previously noted, Lominski and Roberts reported that only a few of 104 plasmas tested for inhibitory activity were positive, while 212 of 348 sera were inhibitory. In the present study, however, marked differences in the resistance of human plasma were readily demonstrated by a technique of coagulase dilutions reacting with a constant undiluted plasma, except for ten per cent anticoagulant. Indeed, some 93 per cent of adult human plasmas were more or less inhibitory. Some of these proved completely refractory, in spite of adequate content of the blood components which enter into physiological clotting, although a more potent coagulase would undoubtedly have given a measurable end-point. In spite of a general parallelism between the two techniques, it has been noted that an "immune" rabbit serum was far more effective in the Lominski test than was a human serum prepared from an inhibitory plasma of the same activity as the rabbit plasma. One cannot therefore be entirely certain that the human plasma resistance is mediated by the same agent as that operating in the development of resistance in an immunized rabbit.
The problem of antibody versus non-specific inhibitors, therefore continues to be difficult to resolve on the basis of available evidence. Efforts at direct identification of the inhibitors of human plasma with antibodies by a collodion particle agglutination technique were not possible, since, with one exception, no agglutination took place. Although recent work has brought support to the view that coagulase may be antigenic,7 l3 the operation of other inhibitory mechanisms, such as ascorbic acid and proteolytic enzymes, is equally well estab-lished."2 One may, however, with reasonable certainty rule out significant fluctuations of the "activator" or coagulase-reacting factor as being responsible for the plasma resistance which has been observed. This by no means implies that under some pathological conditions variations in the reacting factor may not occur, and indeed that these may not prove of clinical significance.
The present observations point to the desirability of further studies which may shed some added light on the mechanism of the plasma resistance. Thus, it would be of special interest to extend the examination of plasmas to various age groups, including particularly infants and children, to note whether the development of coagulase resistance -parallels the well-defined pattern set by other antibodies, such as that of diphtheria antitoxin. A more direct approach would be a study of plasma resistance in relation to staphylococcal infection. Unfortunately, the few observations which were made on this phase of the problem proved inconclusive. The studies of Rammelkamp,7 however, suggest that serum inhibition of coagulase rises in the wake of staphylococcal infection in man and in the monkey.
Summary
The resistance of human plasma to staphylocoagulase was studied by a test in which serial dilutions of a cell-free coagulase preparation were reacted with undiluted plasma.
Of 307 adult human plasmas, about 7 per cent were non-inhibitory, reacting with a coagulase dilution of 1:5120 to 1:10,240. Ninety-three per cent of the plasmas showed evidence of resistance to coagulase, ranging from complete refractoriness to varying degrees of inhibition.
The possible mechanisms of this resistance are discussed.
